Emil Martinka
Aim: To compare doses of basal analogues, insulin Lantus versus Levemir, necessary for obtaining comparable glycemic control. Materials and Methods: Retrospective analysis comparing doses of basal analogues of insulin Lantus versus Levemir in n = 1000 randomly selected patients treated with these insulins in ambulatory practice from whole Slovakia, with diabetes mellitus type1 (DM-1) and type 2 (DM-2) in complete substitution treatment with insulin (basal analogue + prandial), divided to subgroups. Subgroup 1. Patients after excluding patients with HbA1c > 10 %, and those before treated with other compared basal analogue (e.g. patients at the time of monitoring treated with insulin Levemir, before with insulin Lantus). Subgroup 2. Patients from the subgroup 1 after excluding patients with FPG > 10 mmol/l in dose of basal insulin in the evening < 0.3 U/kg TH u DM-1 or < 0.5 U/kg TH in DM-2. Subgroup 3. Patients from subgroup 2, with HbA1c < 8.5 % and FPG < 8 mmol/l. Subgroup 4. Patients from subgroup 3 given the basal analogue once a day. Results: both basal analogues of insulin (insulin Lantus and insulin Levemir) in comparable glycemic control required comparable doses of single basal analogies as well as in related prandial insulins and whole day doses of insulin. Some differences in patients with DM-1, obtained within the whole group and subgroup 1 disappeared after homogenization if patients regarding glycemic control and adequate titration. In patients with DM-2 doses of both basal insulins were in all comparable groups comparable. The rate of patients with administration of basal insulin twice a day was almost in all subgroups in the branch of patients on insulin Levemir significantly higher than in the branch Lantus. Summary: Results of our analysis did not prove essential differences between doses of compared basal insulins (Lantus versus Levemir). Both basal insulins in comparable glycemic control required comparable doses of basal and related prandial insulin in patients with DM-1 as well as in patients with DM-2.